Newsletter | June 10, 2021

06.10.21 -- Clinical-To-Commercial Perspective On Autologous Cell Therapies

Confronting Scalability With Autologous Therapies

Autologous immunotherapies have evolved to provide breakthrough treatments, but complexity of the production process often results in extended timelines and high manufacturing costs, limiting scalability and application across therapeutic indications. Explore the current challenges and solutions available for scale-up.

The Raw Material Hurdle: Plasmids For Viral Vector-Based Gene Therapies

The success of using viral vectors to deliver a molecular payload into a cell or replace defective genes with functional ones is an inflection point in the future of modern medicine. New technologies and additional capacity to address cell and gene therapy market growth and raw material shortages are necessary to support your product now and well into the future.

Overcoming Commercialization Challenges For Cell & Gene Therapies

While cell and gene therapies offer great promises, treatments, and cures, challenges exist from development through the delivery of the drug products to patients. This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps and strategies and solutions to facilitate development through commercialization.